TP53 and diffuse large B-cell lymphoma: Taken together, the potent cytotoxicity observed in various TP53-mutant DLBCL models underscores the therapeutic potential of USP7 inhibition in targeting DDR1, offering a promising approach for the treatment of TP53-mutant r/r DLBCL.